Part of Agilent

Things that you need to know

On December 19, 2022, Agilent Technologies Inc. announced the acquisition of Avida Biomed, an early-stage life sciences company that develops high-performance target enrichment workflows with unique capabilities for clinical researchers utilizing next-generation sequencing approaches to study cancer.

Avida’s innovative genomics tools enable simultaneous genomic and DNA methylation profiling from a single sample without compromising sensitivity or specificity. The company’s streamlined assay protocol, which also includes library preparation, can be completed in a single shift enabling fast turnaround of assay results. This automatable workflow has been validated for use with various sample types including liquid biopsy, which has some of the most demanding performance specifications.

The acquisition complements Agilent’s market leading SureSelect portfolio and further augments Agilent’s strategy to expand into the high-growth clinical research and diagnostics markets.

Avida Biomed is now fully integrated to Agilent since June 2023 and Agilent has launched in March 2024 the Agilent Avida portfolio.

Learn more about Avida portfolio

Below are answers to common questions associated to what you can expect after this integration.

Q: Who do I contact to inquire about Avida Biomed?

The Avida biomed integration is now complete, and Agilent has launched the Agilent Avida portfolio as of March 2024. Please contact your Agilent representative to learn more about the Agilent Avida portfolio.

Q: Who do I contact for technical support, or a service issue related to Avida products?

Please contact your Agilent representative for questions and support related to the Agilent Avida portfolio.

Q: Can Agilent customers include Avida products on their Agilent orders?

Yes, the recently launched Agilent Avida products are available for sale through the Agilent distribution network. Please contact your Agilent representative to learn more about the Agilent Avida portfolio..